Efficacy and safety of pomalidomide as a replacement therapy for lenalidomide for relapsed/refractory multiple myeloma patients refractory to a lenalidomide-containing combination regimen

Autor:	Roy Mackintosh, Nashat Y. Gabrail, Haresh S. Jhangiani, Robert Vescio, Alberto Bessudo, Ashkan Lashkari, James R. Berenson, Tanya M. Spektor, Michael Oren Robinson, Tina Maluso, Regina A. Swift, Samir V. Kubba, Jeffrey D. Neidhart, Alexa Cohen, Ibrahim Nakhoul
Rok vydání:	2018
Předmět:	Oncology Cancer Research medicine.medical_specialty business.industry Immunomodulatory drug Refractory Multiple Myeloma Pomalidomide medicine.disease 03 medical and health sciences Regimen 0302 clinical medicine Refractory 030220 oncology & carcinogenesis Internal medicine Relapsed refractory medicine business Multiple myeloma 030215 immunology medicine.drug Lenalidomide
Zdroj:	Journal of Clinical Oncology. 36:e20012-e20012
ISSN:	1527-7755 0732-183X
DOI:	10.1200/jco.2018.36.15_suppl.e20012
Popis:	e20012Background: Pomalidomide (POM) is a third–generation immunomodulatory drug shown to be safe and effective for the treatment of relapsed/refractory multiple myeloma (RRMM) patients (pts) previ...
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::a8e2636c695ed7aa7a66c426b01ecd03 https://doi.org/10.1200/jco.2018.36.15_suppl.e20012 Zobrazit plný text záznamu